Status:
COMPLETED
Aripiprazole as Augmentation for TRD
Lead Sponsor:
State University of New York - Upstate Medical University
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Depression
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
A sizeable minority of patients suffering from major depression do not have their full set of depressive symptoms relieved by a single medication. Often times, a second medication is added to a patien...
Detailed Description
This is a prospective, open-label study that will examine the clinical utility and safety of adding the atypical antipsychotic aripiprazole as an augmenting agent to antidepressant therapy in treatmen...
Eligibility Criteria
Inclusion
- males or females age 18 to 65 years, DSM-IV episode of Major Depression non-psychotic, ≥14 score on the 17-item HRSD, adequate trial with two antidepressants (see definition above of 'adequate trial'), ability to receive and give informed consent, if patients are of child-bearing potential (male or female), use of an effective contraceptive is required for at least one month prior to the screening Visit and documentation of a negative pregnancy (female) test upon entry into the study.
Exclusion
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
May 1 2005
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00174876
Start Date
July 1 2004
End Date
May 1 2005
Last Update
September 18 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SUNY Upstate Medical University
Syracuse, New York, United States, 13210